目的 分析南京市第一医院抗帕金森病药的使用情况，为临床合理用药提供参考。方法 对2015-2017年南京市第一医院抗帕金森病药的种类、用药金额、用药频度（DDDs）、日均费用（DDC）及药品排序比（B/A）等进行统计分析。结果 2015-2017年南京市第一医院抗帕金森病药用药金额占全院神经系统用药金额比例呈上升趋势。抗帕金森病药物中，用药金额排前3位是多巴丝肼片、吡贝地尔缓释片和盐酸普拉克索片；DDDs排前3位是多巴丝肼片、吡贝地尔缓释片和盐酸金刚烷胺片；抗帕金森病药DDC值基本保持不变，其中盐酸普拉克索片DDC值最高，为63.19元；盐酸金刚烷胺片DDC值最低，为0.12元。盐酸普拉克索片和甲磺酸溴隐亭片的B/A值最小，2015-2017年度分别为0.50、0.50、0.40和0.57、0.57、0.57；盐酸金刚烷胺片的B/A值最大，分别为2.00、3.00、2.33，其余抗帕金森病药物的B/A值基本接近1.0。结论 2015-2017年南京市第一医院抗帕金森病药物发热总体用药和价格分布比较客观合理。

Objective To analyze the use of anti-Parkinson's disease drugs in Nanjing First Hospital, and to provide reference for rational clinical drug use in clinic. Methods The utilization of anti-Parkinson's disease drugs in Nanjing First hospital from 2015 to 2017 was analyzed statistically in respects of drug types, consumption sum, DDDs, DDC, and B/A. Results The proportion of the total consumption sum of anti-Parkinson's disease drugs in the total consumption sum of nervous system drugs used in Nanjing First Hospital was on the rise from 2015 to 2017. Among the anti-Parkinson's disease drugs, the top three of consumption sums were Levodopa and Benserazide Hydrochloride Tablets, Piribedil Sustained-release Tablets, and Pramipexole Hydrochloride Tablets. The top three DDDs were Levodopa and Benserazide Hydrochloride Tablets, Piribedil Sustained-release Tablets, and Amantadine Hydrochloride Tablets. DDC value of anti-Parkinson's disease drugs remained basically unchanged. DDC of Pramipexole Hydrochloride Tablets was the highest with 63.19 yuan, and DDC of Amantadine Hydrochloride Tablets was the lowest with 0.12 yuan. From 2015 to 2017, the B/A values of Pramipexole Hydrochloride Tablets and Bromocriptine Mesylate Tablets were the smallest, which were 0.50, 0.50, 0.40, and 0.57, 0.57, 0.57 respectively. The B/A values of Amantadine Hydrochloride Tablets were the largest, which were 2.00, 3.00, and 2.33, respectively, and the B/A values of the remaining anti-Parkinson's disease drugs was basically near to 1.0. Conclusion The overall drug use and price distribution of anti-Parkinson's drugs in Nanjing First Hospital from 2015 to 2017 are objective and reasonable.

R913